📖 Your Q2 Earnings Guide: Discover the Stocks ProPicks AI Highlights to Jump Post-EarningsRead more

Market Analysis: Johnson & Johnson And Competitors In Pharmaceuticals Industry

Published 17/06/2024, 16:00
© Reuters.  Market Analysis: Johnson & Johnson And Competitors In Pharmaceuticals Industry

Benzinga - by Benzinga Insights, Benzinga Staff Writer.

In today's fast-paced and highly competitive business world, it is crucial for investors and industry followers to conduct comprehensive company evaluations. In this article, we will delve into an extensive industry comparison, evaluating Johnson & Johnson (NYSE:JNJ) in relation to its major competitors in the Pharmaceuticals industry. By closely examining key financial metrics, market standing, and growth prospects, our objective is to provide valuable insights and highlight company's performance in the industry.

Johnson & Johnson Background Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.

CompanyP/EP/BP/SROEEBITDA (in billions)Gross Profit (in billions)Revenue Growth
Johnson & Johnson 21.63 5 4.28 4.69% $5.68 $14.87 2.34%
Eli Lilly and Co 129.37 65.16 22.09 19.02% $3.12 $7.09 25.98%
Merck & Co Inc 143.87 8.12 5.37 12.22% $6.96 $12.23 8.89%
AstraZeneca PLC 39.30 6.59 5.22 5.69% $4.47 $10.46 16.55%
Novartis AG 24.03 5.44 4.60 6.23% $4.66 $9.02 9.71%
GSK PLC 14.60 4.68 2.13 7.69% $2.07 $5.39 5.93%
Zoetis Inc 32.86 15.39 9 11.91% $0.93 $1.55 9.5%
Takeda Pharmaceutical Co Ltd 45.07 0.89 1.52 -0.04% $186.41 $668.37 -5.43%
Dr Reddy's Laboratories Ltd 17.97 3.56 3.58 4.77% $20.32 $41.48 12.49%
Jazz Pharmaceuticals PLC 23.38 1.93 2.03 -0.39% $0.23 $0.81 1.03%
Prestige Consumer Healthcare Inc 15.41 1.94 2.86 3.04% $0.09 $0.15 -3.11%
Corcept Therapeutics Inc 27.59 5.51 6.11 5.22% $0.03 $0.14 38.95%
Average 46.68 10.84 5.86 6.85% $20.84 $68.79 10.95%
table { width: 100%; border-collapse: collapse; font-family: Arial, sans-serif; font-size: 14px; }

th, td { padding: 8px; text-align: left; }

th { background-color: #293a5a; color: #fff; text-align: left; }

tr:nth-child(even) { background-color: #f2f4f8; }

tr:hover { background-color: #e1e4ea; }

td:nth-child(3), td:nth-child(5) { text-align: left; }

.dividend-amount { font-weight: bold; color: #0d6efd; }

.dividend-frequency { font-size: 12px; color: #6c757d; } After examining Johnson & Johnson, the following trends can be inferred:

  • A Price to Earnings ratio of 21.63 significantly below the industry average by 0.46x suggests undervaluation. This can make the stock appealing for those seeking growth.

  • Considering a Price to Book ratio of 5.0, which is well below the industry average by 0.46x, the stock may be undervalued based on its book value compared to its peers.

  • The Price to Sales ratio is 4.28, which is 0.73x the industry average. This suggests a possible undervaluation based on sales performance.

  • The Return on Equity (ROE) of 4.69% is 2.16% below the industry average, suggesting potential inefficiency in utilizing equity to generate profits.

  • With lower Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $5.68 Billion, which is 0.27x below the industry average, the company may face lower profitability or financial challenges.

  • The gross profit of $14.87 Billion is 0.22x below that of its industry, suggesting potential lower revenue after accounting for production costs.

  • With a revenue growth of 2.34%, which is much lower than the industry average of 10.95%, the company is experiencing a notable slowdown in sales expansion.

Debt To Equity Ratio

The debt-to-equity (D/E) ratio indicates the proportion of debt and equity used by a company to finance its assets and operations.

Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.

In terms of the Debt-to-Equity ratio, Johnson & Johnson stands in comparison with its top 4 peers, leading to the following comparisons:

  • In terms of the debt-to-equity ratio, Johnson & Johnson has a lower level of debt compared to its top 4 peers, indicating a stronger financial position.

  • This implies that the company relies less on debt financing and has a more favorable balance between debt and equity with a lower debt-to-equity ratio of 0.48.

Key Takeaways For Johnson & Johnson in the Pharmaceuticals industry, the PE, PB, and PS ratios are all low compared to peers, indicating potential undervaluation. However, the low ROE, EBITDA, gross profit, and revenue growth suggest underperformance relative to industry standards. This may signal a need for further investigation into operational efficiency and growth strategies to align with industry peers.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.